Abstract | BACKGROUND: METHODS: We retrospectively enrolled 17 patients (ten men, seven women; median age, 63 years; range, 27-81 years). They were all proven to have fatty liver through imaging and had little or no history of drinking ( ethanol consumption of < 20 g/day for women and < 30 g/day for men). They were administered pemafibrate from October 2018 to June 2020. RESULTS: After administration, serum triglyceride (TG) tended to be decreased (300.5 ± 22.5 to 239.5 ± 34.3 mg/dL, P = 0.06). Serum high-density lipoprotein ( HDL) cholesterol and low-density lipoprotein ( LDL) cholesterol levels did not change. ALT was significantly decreased (-47.4%) for six months (57.5 ± 8.8 to 30.3 ± 5.8 U/L, P < 0.01). The values of serum GGT significantly decreased (-48.7%) for sixth months (63.9 ± 10.3 to 32.8 ± 6.6 U/L, P < 0.01). Aspartate aminotransferase (AST) to platelet ratio (APRI), a fibrosis marker, also was significantly decreased in the sixth month (0.7 ± 0.1 to 0.4 ± 0.1, P < 0.05). Body mass index (BMI) and hemoglobin A1c (HbA1c) showed no significant change. CONCLUSION:
Pemafibrate dramatically ameliorated the values of liver function tests and APRI in patients with NAFLD.
|
Authors | Suguru Ikeda, Takaaki Sugihara, Yoshiki Hoshino, Yukako Matsuki, Takakazu Nagahara, Jun-Ichi Okano, Sonoko Kitao, Youhei Fujioka, Kazuhiro Yamamoto, Hajime Isomoto |
Journal | Yonago acta medica
(Yonago Acta Med)
Vol. 63
Issue 3
Pg. 188-197
(Aug 2020)
ISSN: 0513-5710 [Print] Japan |
PMID | 32884438
(Publication Type: Journal Article)
|
Copyright | ©2020 Tottori University Medical Press. |